Finanzen von Nuvation Bio Inc (NUVB)NUVBNuvation Bio Inc

Evaluating the bottom line, Nuvation Bio Inc. maintains a gross margin of 86.54%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -161.06%, while the net margin is -49.99%. These profitability ratios, combined with a Return on Equity (ROE) of -47.81%, provide a clear picture of how effectively NUVB converts its operational activities into shareholder value.

In the context of the broader market, NUVB competes directly with industry leaders such as STOK and GENB. With a market capitalization of $1.67B, it holds a significant position in the sector. When comparing efficiency, NUVB's gross margin of 86.54% stands against STOK's 100.00% and GENB's 100.00%. Such benchmarking helps identify whether Nuvation Bio Inc. is trading at a premium or discount relative to its financial performance.

Nuvation Bio has shown fluctuating revenue, with Q1 2026 revenue at $83.23 million and a gross margin of 92.80%. However, the company has faced significant net income losses, with a net income of -$62.84 million in Q2 2026.